[ Frequency Therapeutics raises $32M in Series A ]

Frequency Therapeutics has raised $32 million in Series A funding.

Founded in 2015, Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering.

New funding supports expanded work to realize the disease modifying potential of Progenitor Cell Activation (PCA™) beyond hearing loss.

Funding  Series A
Founded  2015
Country  USA
City  Woburn, Massachusetts
Founder / CEO  David L. Lucchino
Deal Size  $32M
Investors  Cobro Ventures
 Alexandria Real Estate Equities
 Korea Investment Partners
 Emigrant Capital
 Morningside Group
Previous Investors  /

[adyen action=”checkout_button”]